Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: NGM120 for cancer cachexia in colorectal cancer
2025-521730-28-00Phase 2Authorised
- Sponsor
- NGM Biopharmaceuticals
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and colorectal cancer (CRC) comparing NGM120 with Placebo for NGM120 (2 arms). Primary endpoints: Change from baseline in body weight at Week 12 and Treatment-emergent adverse events. Planned start Mar 2026; status: authorised.
02
Drugs
NGM120
03
Conditions
cancer anorexia-cachexia syndrome (CACS)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-521730-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521730-28-00.